Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO
02 juin 2023 07h00 HE
|
Autolus Therapeutics plc
76% of patients treated with obe-cel in the FELIX study achieved a response (CR/CRi), primary endpoint has been met based on previously communicated interim analysisPotential best in class...
Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress
04 mai 2023 07h00 HE
|
Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL), on track for next data update at ASCO and EHA, with a Biologics License...
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting
26 avr. 2023 07h06 HE
|
Autolus Therapeutics plc
- Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALL - Complete responses observed in patients with CD19 negative disease - No antigen negative...
Autolus Therapeutics to Host Virtual Capital Markets Day
25 avr. 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, will host a...
Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
20 avr. 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, April 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Publication in Molecular Therapy
04 avr. 2023 07h00 HE
|
Autolus Therapeutics plc
- Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR - AUTO1/22 may reduce CD19 negative escape in children with B-ALL, and may have broader applications in...
Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress
07 mars 2023 07h00 HE
|
Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) met the primary endpoint in the pivotal Phase 2 FELIX study and is on track...
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
12 déc. 2022 10h00 HE
|
Autolus Therapeutics plc
Obe-cel: 35% of relapsed/refractory adult B-ALL patients in the ALLCAR19 trial remain in complete remission at a median follow up of three years without the need for additional anti-leukemia...
Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences
08 déc. 2022 16h02 HE
|
Autolus Therapeutics plc
Development milestone of $35m achieved earlier than anticipated as a result of the positive interim analysis of Autolus’ pivotal FELIX Phase 2 trial, announced in a separate press release...
Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis
08 déc. 2022 16h01 HE
|
Autolus Therapeutics plc
Obe-cel demonstrated Overall Remission Rate (ORR) of 70% in interim analysis of 50 patients with relapsed/refractory (r/r) adult Acute Lymphoblastic Leukemia (ALL)Encouraging safety data observed,...